Weight loss drugs and CMS coverage: Why all eyes are on Medicare

(By Rylee Wilson for Becker’s Hospital Review)

New GLP-1 drugs to treat diabetes and obesity can be expensive, and most payers do not cover drugs only for weight loss for their members.

Manufacturers of the headline-generating drugs are pushing for Medicare to cover the drug, and Medicaid agencies in a few states cover new weight loss drugs for beneficiaries. Continue reading here…

Notice: The link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid on the posted date; medicarereport.org cannot guarantee the duration of the link’s validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc.; the AMAC Foundation, Inc.; or medicarereport.org